Results 261 to 270 of about 52,475 (270)

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

Lancet Haematology,the, 2016
Hannah Cohen, Beverley J Hunt, Maria Efthymiou   +2 more
exaly  

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Lancet Neurology, The, 2018
Scott E Kasner, Pablo Lavados, Keith W Muir   +2 more
exaly  

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

New England Journal of Medicine, 2012
Eugene Braunwald, Deepak L Bhatt, Paul Burton   +2 more
exaly  

The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor

Nature Reviews Drug Discovery, 2010
exaly  

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban

Thrombosis and Haemostasis, 2012
Raphaël Marlu, Gilles Pernod
exaly  

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Lancet, The, 2015
Jeffrey B Washam, Daniel E Singer, Graeme J Hankey   +2 more
exaly  

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

New England Journal of Medicine, 2018
Hardi Mundl, Scott E Kasner, Shrikant I Bangdiwala   +2 more
exaly  

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

Lancet, The, 2009
exaly  

Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation

European Heart Journal, 2015
Riccardo Cappato, Gerald V Naccarelli, Johan Vijgen   +2 more
exaly  

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

Clinical Pharmacokinetics, 2013
exaly